SAN DIEGO, Feb. 15, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTC-BB:AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting dry eye disease (DED), today announced two key milestones in preparation of the launch of its DED diagnostics testing initiative.
Read more at globenewswire.comAXIM Biotech Announces New Milestones in Preparation of Dry Eye Disease Diagnostics Launch
Globe Newswire - Press Release
All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here